logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Gilead to Acquire Kite and Juno Stock Rallied Too      

When what you predicted, preached, and wished are realized, this is good news. Today’s news is bringing all Prohost predictions into realization, Yes, Kite (KITE) is on its way to be acquired by Gilead (GILD) and yes both stocks have...

Read More

August 28, 2017

0

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares     CRISPRs  are bacterial immune systems that contain many defense enzymes such as the Cas9 “molecular scissors,” which scientists have engineered as  a   powerful DNA-targeting gene-editing tool  ...

Read More

March 28, 2018

0

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Bellicum Pharmaceuticals (BLCM) :  The U.S. Food and Drug Administration (FDA) has l ifted the clinical hold on studies of BPX-501  in the U.S. The decision follows consultation with the FDA and agreement on amendments to the study protocols including guidance on monitoring and...

Read More

April 12, 2018

0

Let’s Go Shopping

In today’s news,  Incyte’s (INCY)  immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda ®  did not meet the endpoints of the trial in patients with unresectable or metastatic melanoma. The stock was subjected to a selloff...

Read More

April 6, 2018

0

Alnylam’s RNAi Product Patisiran Has More Positive News

The Market The Stock Market is Still under pressure, which is frightening common investors, pressuring them to sell. We see no real reasons for the stock market to be acting as a Bear when the criteria of bullishness are obvious...

Read More

April 25, 2018

0

ImmunoGen Stock Flied on Ovarian Cancer Drug News

The Independent Data Monitoring Committee (IDMC) decided that  ImmunoGen (IMGN)  Phase 3 registration trial evaluating  mirvetuximab soravtansine  as a single-agent therapy for  platinum-resistant ovarian cancer  will continue as planned without modification. ImmunoGen has completed full enrollment of the trial two...

Read More

April 27, 2018

0

The FDA Approves Portola Pharmaceuticals’ Andexxa®. The First and ONLY Antidote for the Reversal of Factor Xa Inhibitors

The U.S. Food and Drug Administration (FDA) has approved  Portola’s (PTLA)  drug Andexxa ® , the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Commenting on...

Read More

May 4, 2018

0

A Gratifying Exelixis Quarterly Results

It is obvious that  Exelixis’ (EXEL)  first quarter results  do not justify the selling of EXEL  during the whole quarter, but rather condemn it. It is an undeniable fact that Exelixis is doing a great job squeezing the best out...

Read More

May 3, 2018

0

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

EXELIXIS AGAIN They said : Sell EXEL, as no partner is interested in the firm’s FDA approved cabozantinib to date. What really happened: It did not take long for IPSEN to come forward and take the responsibility of marketing cabozantinib...

Read More

May 9, 2016

0

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

Seres Therapeutics (MCRB) , is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity...

Read More

May 13, 2016

0

  • Previous
  • 1
  • 2
  • ...
  • 36
  • 37
  • 38
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy